Editorials

Is a Patient Questionnaire Without a Joint Examination as Undesirable as a Joint Examination Without a Patient Questionnaire?
T. Pincus, K.A. Gibson, J-M.M. Berthelot .......................... 619

Resolution of Proteinuria in Lupus Nephritis: Hurry Up and Wait
J.M. Bargman, C. Avila-Casado ........................................ 622

Further Evidence for Influenza and Pneumococcal Vaccination in Patients Treated with Disease Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor Agents M.C. Kapetanovic .............................................. 626

Articles

Subcutaneous Abatacept for the Treatment of RA: Longterm Data from the ACQUIRE Trial M.C. Genovese, C. Pacheco Tena, A. Covarrubias, et al .................. 629

Is Tightly Controlled Disease Activity Possible with Online Patient-reported Outcomes?
M.J. Walter, S.H. Mohd Din, J.M. Hazes, E. Lesaffre, P.J. Barendregt, J.J. Luime ................................. 640

Vaccine Responses in Patients with RA Treated with Certolizumab Pegol: Results from a Single-blind Randomized Phase IV Trial

Retinol-binding Protein 4 in RA-related Insulin Resistance and β-cell Function
I. Ferraz-Amaro, M.A. González-Gay, F. Diaz-González ........ 658

Abatacept Reduces Levels of Switched Memory B Cells, Autoantibodies, and Immunoglobulins in Patients with RA
M. Scarsi, L. Paolini, D. Ricotta, et al ................................. 666

Systemic Autoimmune Rheumatic Disease Prevalence in Canada: Updated Analyses Across 7 Provinces
L. Broten, J.A. Aviña-Zubieta, D. Lacaille, et al .......................... 673

Mortality and Cardiovascular Burden of SLE in a US Population-based Cohort
C.M. Bartels, K.A. Buhr, J.W. Goldberg, et al .......................... 680

Time to Recovery from Proteinuria in Patients with Lupus Nephritis Receiving Standard Treatment

Frailty Index to Measure Health Status in People with SSc
M.R. Rockwood, E. MacDonald, E. Sutton, K. Rockwood, Canadian Sclerodema Research Group, M. Baron .................. 698

Impaired Left Ventricular Apical Rotation is Associated with Disease Activity of PsA Q. Shang, L.S. Tam, J.E. Sanderson, A.P-W. Lee, E.K-M. Li, C-M. Yu .................. 706

Hemostatic and Fibrinolytic Changes Are Related to Inflammatory Conditions in Patients with PsA — Effect of Different Treatments M.N. Di Minno, S. Iervolino, R. Peluso, A. Di Minno, P. Ambrosino, R. Scarpa, and the CaRRDs Study Group ........................ 714

Factors Associated with Major CV Events in Patients with Systemic Necrotizing Vasculitides: Results of a Longterm Followup Study B. Terrier, G. Chironi, C. Pagnoux, et al, for the French Vasculitis Study Group .................. 723

Joint Involvement in Patients with Early PMR Using High-resolution Ultrasound and Its Contribution to the EULAR/ACR 2012 Classification Criteria for PMR
S. Weigand, B. Ehrenstein, M. Fleck, W. Hartung .................. 730

Colchicine in Behçet Syndrome: A Longterm Survey of Patients in a Controlled Trial
V. Hamuryudan, G. Hatemi, K. Tascilar, et al .......................... 735

Treatment of Asymptomatic Hyperuricemia and Prevention of Vascular Disease: A Decision Analytic Approach
R. Akkineni, S. Tapp, A.N.A. Tosteson, et al .......................... 739

Joint Effects of Alcohol Consumption and ABCG2 Q141K on Chronic Tophaceous Gout Risk

Pediatric Rheumatology

Longterm Safety and Effectiveness of the Anti-interleukin 6 Receptor Monoclonal Antibody Tocilizumab in Patients with Systemic JIA in Japan
S. Yokota, T. Imagawa, M. Mori, et al ................................. 759

Transcending Youth with Rheumatic Conditions: Perspectives of Pediatric Rheumatology Providers in the United States and Canada
P. Chira, T. Ronis, S. Ardoin, P. White ................................. 768